Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib

Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib

Nutritional assessment of patients with non-small cell lung cancer treated with osimertinib.

Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale.

Inclusion Criteria:

• Patients over 18 years of age.
• Patients diagnosed with NSCLC.
• Patients undergoing osimertinib treatment who collect their medication at the Pharmacy Outpatient Clinic of the Álvaro Cunqueiro Hospital.
• Patients who have consented to participate by signing the informed consent form.

Exclusion Criteria:

• Patients who have discontinued osimertinib treatment.
• Patients currently receiving osimertinib treatment for an indication other than those authorized in the product information (compassionate use).
• Patients who do not sign the informed consent form.

Withdrawal criteria:

- Revocation of consent to participate in the study by the patient.